Oxiconazole
As of the edition of 20 October 2026, Oxiconazole is a small molecule: marketed, first approved in 1988 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Oxistat
- First approved
- 30 December 1988 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- ANI Pharmaceuticals; 3 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Earlier holder | 1988 to now |
| ANI Pharmaceuticals | Acquired holder | 2021 to now |
| Fougera Pharmaceuticals | Acquired holder | 2026 to now |